A follow-up study of the treatment with tenofovir Vs. adefovir in chronic hepatitis B patients in Indonesia

RMJ. 2026; 51(2): 321-325

doi: 10.5455/rmj.20250711024657

Ummi Maimunah, Firda Iragama Wessels, Juniastuti Juniastuti, Brahmana Askandar Tjokroprawiro, Hoda M. Malaty, Muhammad Miftahussurur.

Abstract	Download PDF		Post
Objective: To evaluate and compare TDF and ADV therapies among patients diagnosed with CHB and examined the outcomes after one-year of treatment. Methodology: We retrieved the records of CHB patients registered in the Hepatology Clinic in Dr. Soetomo General Hospital, Indonesia, between January 2010 and December 2018. The diagnosis of CHB was assessed based on the presence of HBsAg for at least six months. After one-year of continuous treatment of TDF 300 mg/day or ADV 10 mg/day continuously for a year, we evaluated the outcomes that were based on the biochemical, improvement of fibrosis and virological status in patients who were either negative or positive HBeAg. Results: After one-year of therapy, we found significant differences in HBV DNA improvement between TDF and ADV treated patients in HBeAg-positive patients (17/26, 65.4% vs. 5/17, 29.4%; p Key words: Adefovir, chronic hepatitis B, hepatitis, tenofovir.